{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:05:08Z","timestamp":1794341108898,"version":"4.9.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.biopha.2022.114051","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T23:48:24Z","timestamp":1670888904000},"page":"114051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Valproate, divalproex, valpromide: Are the differences in indications justified?"],"prefix":"10.1016","volume":"158","author":[{"given":"Cl\u00e9ment","family":"Delage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Palayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Etain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Hagenimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Smati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Chouchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie C.","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.114051_bib1","first-page":"365","article-title":"Brief history of the development of valproate in bipolar disorders","volume":"27","author":"Lemp\u00e9ri\u00e8re","year":"2001","journal-title":"Encephale"},{"key":"10.1016\/j.biopha.2022.114051_bib2","first-page":"435","article-title":"Pharmacodynamic properties of N-dipropylacetic acid","volume":"18","author":"Meunier","year":"1963","journal-title":"Therapie"},{"key":"10.1016\/j.biopha.2022.114051_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/tera.1420350319","article-title":"Valproic acid","volume":"35","author":"Lammer","year":"1987","journal-title":"Teratology"},{"key":"10.1016\/j.biopha.2022.114051_bib4","unstructured":"Food and Drug Administration (FDA), Depakene (valproic acid) Prescribing Information, (2016). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/018081s065_018082s048lbl.pdf (accessed April 8, 2022)."},{"key":"10.1016\/j.biopha.2022.114051_bib5","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.bmc.2004.05.003","article-title":"Characterization of the anticonvulsant profile of valpromide derivatives","volume":"12","author":"Tasso","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2022.114051_bib6","first-page":"707","article-title":"Neuropsychotropic action of a new anti-epileptic agent: depamide","volume":"124","author":"Lambert","year":"1966","journal-title":"Ann. Med. Psychol. (Paris)."},{"key":"10.1016\/j.biopha.2022.114051_bib7","first-page":"442","article-title":"Long-term thymoregulative action of Depamide in manic-depressive psychoses","volume":"2","author":"Lambert","year":"1971","journal-title":"Ann. Med. Psychol. (Paris)."},{"key":"10.1016\/j.biopha.2022.114051_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00343800","article-title":"Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders","volume":"229","author":"Emrich","year":"1980","journal-title":"Arch. Psychiatr. Nervenkr."},{"key":"10.1016\/j.biopha.2022.114051_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0165-0327(85)90022-9","article-title":"The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders","volume":"8","author":"Emrich","year":"1985","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.biopha.2022.114051_bib10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1212\/WNL.33.6.808","article-title":"Gastrointestinal tolerance of divalproex sodium","volume":"33","author":"Wilder","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2022.114051_bib11","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/ajhp\/54.15.1716","article-title":"Clinical and economic impact of replacing divalproex sodium with valproic acid","volume":"54","author":"Cranor","year":"1997","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.biopha.2022.114051_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2165\/00003088-199120020-00003","article-title":"Clinical pharmacology of valpromide","volume":"20","author":"Bialer","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2022.114051_bib16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0028-3908(85)90028-0","article-title":"Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice","volume":"24","author":"L\u00f6scher","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2022.114051_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eplepsyres.2006.02.004","article-title":"Diverse mechanisms of antiepileptic drugs in the development pipeline","volume":"69","author":"Rogawski","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.biopha.2022.114051_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00007691-198103000-00012","article-title":"Dipropylacetic acid* plasma levels; diurnal fluctuations during chronic treatment with dipropylacetamide","volume":"3","author":"Pisani","year":"1981","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2022.114051_bib19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF00549603","article-title":"Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers","volume":"27","author":"Bialer","year":"1984","journal-title":"Eur. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2022.114051_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2515\/therapie\/2010029","article-title":"pour le groupe Suivi Th\u00e9rapeutique Pharmacologique de la Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et de Th\u00e9rapeutique, [Therapeutic drug monitoring of valproate]","volume":"65","author":"Bentu\u00e9-Ferrer","year":"2010","journal-title":"Therapie"},{"key":"10.1016\/j.biopha.2022.114051_bib21","unstructured":"Agence Nationale de S\u00e9curit\u00e9 des M\u00e9dicaments et des Produits de Sant\u00e9 (ANSM), R\u00e9sum\u00e9 des caract\u00e9ristiques du produit - DEPAKINE 500 mg, comprim\u00e9 gastro-r\u00e9sistant, (2021). https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=60184188&typedoc=R (accessed April 8, 2022)."},{"key":"10.1016\/j.biopha.2022.114051_bib22","unstructured":"Agence Nationale de S\u00e9curit\u00e9 des M\u00e9dicaments et des Produits de Sant\u00e9 (ANSM), R\u00e9sum\u00e9 des caract\u00e9ristiques du produit - DEPAKOTE 500 mg, comprim\u00e9 gastro-r\u00e9sistant, (2021). https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=60797287&typedoc=R (accessed April 8, 2022)."},{"key":"10.1016\/j.biopha.2022.114051_bib34","first-page":"46","article-title":"Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans","volume":"20","author":"Bialer","year":"1984","journal-title":"Isr. J. Med. Sci."},{"key":"10.1016\/j.biopha.2022.114051_bib35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2710.2007.00876.x","article-title":"Divalproex sodium vs. valproic acid: Drug utilization patterns, persistence rates and predictors of hospitalization among VA","volume":"32","author":"Iqbal","year":"2007","journal-title":"Patients Diagn. Bipolar Disord., J. Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.114051_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eplepsyres.2006.11.005","article-title":"Distinct absorption characteristics of oral formulations of valproic acid\/divalproex available in the United States","volume":"73","author":"Dutta","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.biopha.2022.114051_bib37","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1185\/03007990802122735","article-title":"Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet","volume":"24","author":"Garikipati","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.biopha.2022.114051_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.jcp.0000117429.05703.5f","article-title":"Divalproex versus valproate in patients with bipolar disorder","volume":"24","author":"Kablinger","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.biopha.2022.114051_bib39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF02336705","article-title":"Some clinical pharmacological aspects of N-dipropylacetamide","volume":"1","author":"Pisani","year":"1979","journal-title":"Ital. J. Neurol. Sci."},{"key":"10.1016\/j.biopha.2022.114051_bib40","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1185\/030079907X210831","article-title":"Cost analysis of divalproex sodium extended-release compared to valproic acid in the treatment of bipolar disorder","volume":"23","author":"Schumock","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.biopha.2022.114051_bib41","first-page":"45","article-title":"Divalproex sodium versus valproic acid in hospital treatment of psychotic disorders","volume":"2","author":"Schwartz","year":"2000","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.biopha.2022.114051_bib42","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1176\/ps.49.10.1355","article-title":"Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients","volume":"49","author":"Sherr","year":"1998","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.biopha.2022.114051_bib43","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1352\/0047-6765(1997)035<0468:EOSFDT>2.0.CO;2","article-title":"Effects of switching from Depakene to generic valproic acid on individuals with mental retardation","volume":"35","author":"Vadney","year":"1997","journal-title":"Ment. Retard."},{"key":"10.1016\/j.biopha.2022.114051_bib44","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4088\/JCP.v61n0410e","article-title":"Gastrointestinal adverse effects with divalproex sodium and valproic acid","volume":"61","author":"Wagner","year":"2000","journal-title":"[4] (Mult. Lett. ), J. Clin. Psychiatry"},{"key":"10.1016\/j.biopha.2022.114051_bib45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1176\/appi.ajp.162.2.330","article-title":"Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions","volume":"162","author":"Wassef","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.biopha.2022.114051_bib46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4088\/JCP.v60n0405","article-title":"The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study","volume":"60","author":"Zarate","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.biopha.2022.114051_bib47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0920-1211(92)90059-3","article-title":"Conventional and controlled release valproate in children with epilepsy: a cross-over study comparing plasma levels and cognitive performances","volume":"13","author":"Brouwer","year":"1992","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.biopha.2022.114051_bib49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/j.1552-4604.1980.tb01663.x","article-title":"Bioavailability of valproic acid under fasting\/ nonfasting regimens","volume":"20","author":"Chun","year":"1980","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2022.114051_bib50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/j.1552-4604.1990.tb03637.x","article-title":"Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote\u00ae Sprinkle)","volume":"30","author":"Carrigan","year":"1990","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.114051_bib51","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/bdd.421","article-title":"Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers","volume":"25","author":"Dutta","year":"2004","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.biopha.2022.114051_bib52","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/0091270004266782","article-title":"Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers","volume":"44","author":"Dutta","year":"2004","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2022.114051_bib53","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0013-7006(04)95454-1","article-title":"Valpromide, valproic acid and removal of hail intestine in the treatment of a chronic depression: a case report","volume":"30","author":"Benjelloun","year":"2004","journal-title":"Encephale"},{"key":"10.1016\/j.biopha.2022.114051_bib54","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1528-1157.1975.tb04743.x","article-title":"Concentration of dipropylacetate in plasma","volume":"16","author":"Loiseau","year":"1975","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopha.2022.114051_bib55","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","article-title":"Clinical pharmacokinetics of valproic acid","volume":"15","author":"Zaccara","year":"1988","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2022.114051_bib57","unstructured":"X. Chastel, A. Essid, P. Lesteven, For the French General Inspectorate of Social Affairs (IGAS), Enqu\u00eate relative aux sp\u00e9cialit\u00e9s pharmaceutiques contenant du valproate de sodium (D\u00e9pakine\u00ae, D\u00e9pakote\u00ae, D\u00e9pamide\u00ae, Micropakine\u00ae et g\u00e9n\u00e9riques), 2015."}],"updated-by":[{"DOI":"10.1016\/j.biopha.2023.115705","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000}}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:34:55Z","timestamp":1779795295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222014408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":41,"alternative-id":["S0753332222014408"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114051","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproate, divalproex, valpromide: Are the differences in indications justified?","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114051"}}